|Generic name||Vincristine sulfate liposome injection|
|Brand name(s), other common name(s)||Marqibo®|
|How the drug is given||Intravenously (IV) (fatal if given by other routes)|
Indications and Usage
Vincristine sulfate liposome injection is FDA approved for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.
Side effects needing medical attention
Constipation; bowel obstruction; nausea; fever; fatigue; diarrhea; decreased appetite; insomnia; low blood cell counts; pneumonia; life-threatening low blood pressure; infection; peripheral sensory and motor neuropathy; lack of strength; muscular weakness; respiratory distress; respiratory failure; pain; abdominal pain; hypotension; mental status changes; cardiac arrest.